Ipsen is on a roll this week, scooping up its second biotech in three days in order to firm up its pipeline with promising clinical-stage candidates.
- Home |
- Ipsen gets the Memo, penning €700M deal to buy rare disease biotech for clinical-stage asset
Ipsen gets the Memo, penning €700M deal to buy rare disease biotech for clinical-stage asset
- July 1, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
